Abstract
Stable remission is the ultimate goal of HIV therapy. A review of recent studies on the ability of HIV to persist despite highly active antiretroviral therapy (HAART) and immune stimulation suggests that achieving this goal will require four developments in basic and clinical science. First, more effective antiretroviral therapies, targeted at proteins other than reverse transcriptase and protease, in order to eliminate the cryptic replication that continues despite best available HAART. Second, agents that activate latent HIV gene expression in quiescent CD4 memory T cells, thereby exposing this viral reservoir to therapeutic intervention by a “shock and kill” strategy. Third, molecules such as immunotoxins that specifically recognize HIV-encoded membrane proteins and thereby potentiate the destruction of infected cells. Fourth, and still most distant, novel approaches such as genetically engineered cytotoxic T lymphocytes or anti-HIV microbes to suppress rekindling of infection by residual virus sequestered in anatomical and cellular reservoirs. Although each of these steps will be difficult to achieve, the many benefits of a cure for HIV make this a worthwhile pursuit.
Keywords: hiv-1, latency, viral reservoir, immunotoxin
Current HIV Research
Title: Can HIV be Cured? Mechanisms of HIV Persistence and Strategies to Combat It
Volume: 2 Issue: 2
Author(s): Dean H. Hamer
Affiliation:
Keywords: hiv-1, latency, viral reservoir, immunotoxin
Abstract: Stable remission is the ultimate goal of HIV therapy. A review of recent studies on the ability of HIV to persist despite highly active antiretroviral therapy (HAART) and immune stimulation suggests that achieving this goal will require four developments in basic and clinical science. First, more effective antiretroviral therapies, targeted at proteins other than reverse transcriptase and protease, in order to eliminate the cryptic replication that continues despite best available HAART. Second, agents that activate latent HIV gene expression in quiescent CD4 memory T cells, thereby exposing this viral reservoir to therapeutic intervention by a “shock and kill” strategy. Third, molecules such as immunotoxins that specifically recognize HIV-encoded membrane proteins and thereby potentiate the destruction of infected cells. Fourth, and still most distant, novel approaches such as genetically engineered cytotoxic T lymphocytes or anti-HIV microbes to suppress rekindling of infection by residual virus sequestered in anatomical and cellular reservoirs. Although each of these steps will be difficult to achieve, the many benefits of a cure for HIV make this a worthwhile pursuit.
Export Options
About this article
Cite this article as:
Hamer H. Dean, Can HIV be Cured? Mechanisms of HIV Persistence and Strategies to Combat It, Current HIV Research 2004; 2 (2) . https://dx.doi.org/10.2174/1570162043484915
DOI https://dx.doi.org/10.2174/1570162043484915 |
Print ISSN 1570-162X |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4251 |
Call for Papers in Thematic Issues
Management of HIV: Management of HIV: old challenges and new needs
The aim of this thematic issue is to provide the most recent updates regarding the effective management of HIV infection. Antiretroviral therapy (ART) has significantly decreased HIV-related mortality, leading to an enhancement in the quality of life and life expectancy for people living with HIV (PLWH). Despite the numerous advancements ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Modulation of Ischemic Brain Injury and Neuroinflammation by Adenosine A2A Receptors
Current Pharmaceutical Design Management and Treatment of Cardiovascular Diseases in the Elderly
Current Pharmacogenomics and Personalized Medicine Pneumonia in the Burn Patient
Current Respiratory Medicine Reviews Interaction Between Bone and Muscle in Older Persons with Mobility Limitations
Current Pharmaceutical Design Emerging Roles for Connexins in Hypertension
Current Hypertension Reviews Current Concepts in the Management of Diabetic Polyneuropathy
Current Diabetes Reviews Phosphodiesterase 5 Inhibitors in the Treatment of Erectile Dysfunction
Current Pharmaceutical Design Use of Paediatric Xylometazoline Nasal Drop is not a Child’s Play in Hypertensive Patients on Bisoprolol: A Case Report
Current Drug Safety NF-κB Inhibitors in Head and Neck Cancer
Letters in Drug Design & Discovery Pharmacological and Toxicological Profile of Harmane-β-Carboline Alkaloid: Friend or Foe
Current Drug Metabolism Discovery and Advancement of Farnesyl Transferase Inhibitors as Potential Anticancer Therapeutic Agents: SCH 66336 a Case Study
Current Medicinal Chemistry - Immunology, Endocrine & Metabolic Agents Exploring New CGRP Family Peptides and their Receptors in Vertebrates
Current Protein & Peptide Science Electroporation in DNA Vaccination Protocols Against Cancer
Current Drug Metabolism Adenosine A<sub>3</sub> Receptor: A promising therapeutic target in cardiovascular disease
Current Cardiology Reviews Circulatory Syndrome: An Evolution of the Metabolic Syndrome Concept!
Current Cardiology Reviews Nutraceutical Approach to Peripheral Neuropathies: Evidence from Clinical Trials
Current Drug Metabolism Coronary Risk Factors in the Elderly: Their Interactions and Treatment
Current Pharmaceutical Design Mechanisms of the Blunting of the Sympatho-Adrenal Response: A Theory
Current Diabetes Reviews The Challenges in Moving from Ageing to Successful Longevity
Current Vascular Pharmacology Angiotensin II Roles in Human Vascular Tone Control
Clinical Immunology, Endocrine & Metabolic Drugs (Discontinued)